Tissue Regenix Group PLC (AIM:TRX) has struck a three-year distribution deal with Australian Allografts for its OrthoPure XT product, pending regulatory approval from Australia's Therapeutic Goods Administration (TGA).
A decellularised xenograft ligament made using Tissue Regenix's dCELL technology, the product is a unique non-human biologic graft used in certain anterior cruciate ligament reconstruction procedures.
The pair will jointly work to secure TGA approval, post which Australian Allografts will import and distribute the products in Australia and New Zealand.
In a statement, Kirsten Lund, EMEA business director for Tissue Regenix, said: "This distribution agreement will allow physicians and patients better access to our innovative products through the Australian Allografts network and is another major step towards Tissue Regenix becoming a global player in the regenerative medicine market.
"We look forward to working with Australian Allografts."